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Objective: Biomarkers associated with cancer screening (CA125, CA15‐3, CA72‐4, total prostate
specific antigen [tPSA]) and the monitoring of pregnancy (pregnancy associated plasma protein‐A
[PAPP‐A]) were measured during natural and stimulated ovarian cycles in disease‐free nonpregnant women to determine if they could reflect normal events relating to ovulation and/or
endometrial changes. Methods: A total of 73 blood samples (10 women) collected throughout
the natural menstrual cycle, and 64 blood samples (11 women) taken during stimulated ovarian
cycles, were analysed on the Roche Cobas e411 automated analyser. Results: Detectable levels
of tPSA were measured in at least one point in the cycle in 6/10 of women in the natural cycle
and 10/11 of women in stimulated cycles, and CA72-4 was detected in only 12/21 women tested.
Concentrations of CA125, tPSA, CA15‐3 and CA72‐4 showed no significant difference between the
natural and stimulated ovarian cycle groups. On average the mean PAPP‐A of the natural group
was (2.41±0.58) mIU/L higher than the stimulated group (t=4.10, P< 0.001). CA125 and CA15‐3
results were both significantly influenced by the stage of the cycle (P<0.0001), whereas tPSA and
PAPP‐A concentrations revealed no significant changes (P曒0.65). CA72‐4 was not affected by
the stage of the cycle nor ovarian stimulation. Conclusion: Ovarian stimulation reduced serum
PAPP‐A levels, CA125 and CA15‐3 levels were generally unaffected by ovarian stimulation but
displayed cyclical changes throughout both natural and stimulated cycles, whilst tPSA and
CA72-4 were not affected by the stage of the cycle or ovarian stimulation.
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1. Introduction
Molecular biomarkers are rarely passive and specific

end-products of a single tissue but are more often potent
compounds involved in a range of biological processes.
Pregnancy-associated plasma protein-A (PAPP-A) is a good
example of such a biomarker in reproductive medicine, and
it is now known to be a protease specific for the cleavage of
insulin-like growth factor binding proteins[1]. Having been
*Corresponding author: Melissa Stemp, Fertility North, Suite 213, Specialist Medical
Centre, Joondalup Health Campus, Shenton Avenue, Joondalup, WA 6027, Western
Australia, Australia.
E-mail: Melissa.Stemp@fertilitynorth.com.au

described in normal pregnancy [2, 3], PAPP-A is useful as a
biomarker in a combined test with free 毬-hCG and fetal
nuchal translucency in the identification of increased risk
of Down’s syndrome[4] and miscarriage[5]. Although most
of the research surrounding PAPP-A has been performed
during pregnancy[6-12], there are recent studies which indicate
differences in PAPP-A concentrations during ART treatment
cycles[13-16]. Furthermore, PAPP-A is produced by granulosa
cells, having a role in follicle selection through its effect
upon IGF availability[17].
PAPP - A is not the only enzyme whose name is
misleading: prostate specific antigen (PSA) was originally
thought to be produced exclusively by prostatic tissue and
was therefore used to monitor prostate cancer[18]. PSA is
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actually a serine protease that is also known as kallikrein-3
(KLK3)[19], and has been associated with a number of tissues
and biological events in women[20] such as in the breast[21],
during the ovarian cycle[22, 23], and in pregnancy[24].
Another tumour biomarker, CA15-3, is a mucin-like
glycoprotein encoded by the MUC1 gene and has a clear
association with reproduction. MUC1 is heterogeneously
expressed on the surface of epithelial cells, including those
in the breast and upper reproductive tract and is thought
to prevent embryo implantation[25]. In addition, expression
of MUC1 has been shown to be progesterone dependent
and is up-regulated in endometrial epithelial cells in the
luteal phase of the menstrual cycle[26, 27]. However, the main
clinical use of the assay is in the monitoring of women with
breast cancer[28-30]. CA125, a high molecular mass mucin-type
molecule, is a tumour biomarker that is used extensively to
monitor epithelial ovarian cancer [31], but it also is expressed
elsewhere such as during the ovarian cycle[32], in association
with endometriosis[33], in pregnancies that are destined to
miscarry[34], and with pelvic inflammatory disease[35].
CA72-4 was once described as a useful tumour marker
for all epithelial derived tumours and gastric carcinomas[36].
This research demonstrated that the sensitivity of CA72-4
for gastric carcinoma was 38%, which is greater than the
tumour markers CA19-9 which is 33%, CEA at 31% and
CA125 at 21%[36, 37]. However, CA72-4 has also been proposed
as a complimentary biomarker to CA125 in the screening of
ovarian cancer, where it was found that by combining the
biomarkers the sensitivity for detecting early stage disease
increased from 45% to 70%[38].
The aim of the present study was to measure five serum
biomarkers (PAPP-A, tPSA, CA15-3, CA125 and CA72-4) in
women during periods of ovarian and endometrial activity,
namely in natural ovarian cycles and stimulated cycles.
Results were analysed to (i) compare the concentrations
between the two reproductive situations, and (ii) identify
any temporal changes that may have occurred relating to
follicular development.
2. Materials and methods
Patient information and consents were approved by both
the Joondalup Health Campus Research Ethics Committee
and the Edith Cowan University Human Research Ethics
Committee. All blood samples were taken as part of the
routine management of the women at F ertility N orth,
but consent was obtained for the analysis of additional
compounds not indicated medically.

2.1. Patients
W omen were recruited during their routine clinical
management, and none of the women had evidence of
cancer or endometriosis. Blood samples collected during
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natural cycles were from women (n=10) who were undergoing
assessment of their natural cycle prior to commencing
fertility treatment. These women were on no medications
that affect ovarian and uterine function such as the oral
contraceptive pill or hormone replacement therapy. Cycle
length was normalised for the purpose of statistical analysis
according to Hadlow et al[39] using the following formula to
calculate the day of the cycle:
Adjusted day = Actual day 伊 (14/Actual day of ovulation)
The cycle was also divided into phases using the adjusted
day of the cycle[40]. Women providing blood in stimulated
cycles (n=11) were undergoing IVF using standard clinical
protocols[41].
2.2. Sample processing and analysis
Blood was collected using syringes and transferred into 5
mL Vacutainer SST™ tubes (Becton Dickinson, UK) before
delivery to the laboratory. The blood was allowed to clot
at room temperature and then centrifuged at 1 300 g for 4
minutes, with the tubes then being ready for loading directly
onto the automated analyser upon removal of the lids. Serum
oestradiol, luteinising hormone, progesterone, and human
chorionic gonadotrophin (hCG) were measured on a Siemens
C entaur CP automated analyser ( S iemens, B ayswater,
Victoria 3053, Australia) within 1 hour of the blood being
collected, and all between-run coefficients of variation were
<5%. The serum was then stored in secondary tubes at -80 曟
before being analysed in one batch on a Roche Cobas e411
automated analyser (Roche Diagnostics, Germany) for the
biomarkers PAPP-A, CA125, CA15-3, CA72-4 and total PSA
(tPSA). Assay variability for the biomarkers was determined
by analysing pooled patient serum in the analytical range
for this study, sometimes close to the limit of detection, and
the within-run variability at these concentrations for the
biomarkers (CA125 <3%; CA15-3 <2%; CA72-4 <5%; PAPP-A
<3%; tPSA <13%) was invariably less than the between-run
variability (CA125 <5%; CA15-3 <7%; CA72-4 <24%; PAPP-A
<27%; tPSA <39%). Assay sensitivity for CA125, CA15-3,
CA72-4, PAPP-A, and tPSA were 0.6 U/mL, 1.00 U/mL, 0.2
U/mL, 4.00 mIU/L, and 0.003 ng/mL respectively.

2.3. Statistical analysis
The ovarian cycle data were analysed with a linear mixed
effects model to compare the marker concentrations in
stimulated and natural cycles across the cycle phases. For
each model, the response variable (CA125, tPSA, CA15-3,
CA72-4 and PAPP-A) was log transformed before analysis.
Group (“natural” and “stimulated”) and cycle phase were
included as fixed effect factors and ‘Subject’ and ‘Time’
were modelled as random effects as in some subjects there
were multiple time points measured within phases. The
interaction between group and phase was also modelled.
The analyses were performed using the R version 3.0.0
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computing software[42].
3. Results
3.1. Ovulation and reproductive hormones
The day of ovulation for the 10 natural cycles is shown in
Figure 1 (a). It was extremely variable, ranging from day 10
to day 25. The day of ovulation in the 11 cycles stimulated
with exogenous gonadotrophin is shown in Figure 1 (b),

and was less variable than the natural cycles ranging
(a)Natural cycle
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(b)Stimulated cycle
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Women(n)
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between day 12 and day 15 of the cycle. The reproductive
hormones oestradiol and progesterone that were measured
as part of routine patient management are shown in Table
1. They follow classical patterns of change throughout the
natural cycle, confirming that the modelling and expression
of results according to the stage of cycle is appropriate.
Differences between the natural cycles and stimulated cycles
were noted and include higher oestradiol values in the midfollicular and late follicular phases of the stimulated cycles,
and higher progesterone in the luteal phase of the stimulated
cycles as a consequence of multiple corpora lutea and the
continued administration of progesterone luteal support.
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Figure 1. The distribution of the day of ovulation for women during (a) natural cycles (n=10), and (b) stimulated cycles (n=11).

Table 1
Reproductive hormone concentrations (mean依sem) in natural (n=10)
and stimulated (n=11) ovarian cycles.
Stage

Oestradiol (pmol/L)
Natural

Stimulated

265.0依43.0

1 133.7依241.1

484.8依68.4

2 187.0依301.1

EF

165.6依11.8

LF

528.0依51.2

MF

ML

156.0依6.6

3 980.0依435.8

Progesterone (nmol/L)

Natural
1.9依0.3

1.4依0.2

1.3依0.2

36.5依4.6

Stimulated
2.3依0.6

-

197.2依30.0

The stage of the cycle was classified as early follicular (EF), mid-

follicular (MF), late follicular (LF) and mid-luteal (ML).

3.2. Biomarkers during ovarian cycles
T he concentrations of the serum biomarkers CA 125 ,
CA15-3 and CA72-4 during natural and stimulated cycles

are shown in Table 2. CA125 concentrations showed no
significant difference between natural and stimulated ovarian
cycles (P=0.5989) but results were significantly influenced
by the stage of the cycle (P<0.0001). Concentrations of CA125
were on average highest during the early follicular phase of
the cycle which is concurrent with menstruation (25.92±4.45)
U /m L and lowest in the late-follicular phase before
ovulation (16.76±2.38) U/mL in natural menstrual cycles. In
stimulated ovarian cycles, concentrations of CA125 were
highest during the mid-luteal phase (22.89±13.45) U/mL
and lowest at the mid-follicular phase (13.41±1.90) U/mL.
All samples in the ovarian cycles had detectable levels of
CA15-3. There was no overall significant difference in the
concentration of CA15-3 between the natural and stimulated
ovarian cycles (P=0.8694). However there was an overall
significant difference within each cycle between phases,
suggesting CA15-3 levels significantly change between
phases (P<0.0001). There were 6/10 (60%) of the individuals

Table 2
The concentrations (mean依sem) of the serum biomarkers CA125, CA15-3 and CA72-4 measured during natural (10 women) and stimulated (11
women) ovarian cycles.
Stage of cycle

CA125 (U/mL)

Natural

Stimulated

MF

21.36依3.21

13.41依1.90

ML

20.39依1.83

EF
LF

25.92依4.45

16.76依2.38

17.06依2.37
13.62依1.64

22.89依13.45

CA15-3 (U/mL)

Natural

Stimulated

17.52依2.31

14.18依2.09

15.59依1.67
15.91依1.69

16.85依1.94

CA72-4 (U/mL)

Natural

Stimulated

1.21依0.50

1.13依0.39

a

15.10依2.00

1.86依0.92

14.60依1.90

1.10依0.33

16.99依2.15

1.04依0.3

b

2.33依1.12
0.98依0.27

1.72依0.88

The stages of the cycles were early follicular (EF), mid-follicular (MF), late follicular (LF), and mid-luteal (ML). Detectable concentrations were

only seen in 6/10 women; bDetectable concentrations were seen in 10/11 women.

a
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in natural menstrual cycles and 6/11 (54.5%) of individuals in
the stimulated cycles that had detectable levels of CA72-4
for at least one of the samples. When detectable, CA72-4
concentrations were overall on average (1.47±0.31) U/mL in
natural cycles and (1.58±0.35) U/mL in stimulated ovarian
cycles. There was a larger degree of variation between the
individuals than there was at different phases of the cycles.
The concentrations of the serum biomarkers tPSA and
PAPP-A are shown in Table 3. Detectable levels of tPSA
were measured in at least one point in the cycle in 6/10
of women in the natural cycle and 10 / 11 of women in
stimulated cycles. Concentrations of tPSA were low during
natural and stimulated cycles and there was no significant
difference either between natural cycles and stimulated
cycles (P=0.9193), or between different stages of the cycle
(P=0.8769). On average the mean PAPP-A of the natural
group was (2.41±0.58) mIU/L higher than the stimulated
group (t=4.10, P<0.001). For PAPP-A, there was no evidence
for an interaction effect between PAPP-A concentrations
and the phase of the cycle (t=-0.08, P=0.93), or for a change
in PAPP-A within natural and stimulated ovarian cycles
across the phases of the cycle (t= -0.44, P=0.65).
Table 3
The concentrations (mean依sem) of the serum biomarkers tPSA and

PAPP-A measured during natural (10 women) and stimulated (11

women) ovarian cycles.
Stage of cycle

tPSA (ng/mL)

Natural

a

Stimulated

b

PAPP-A (mIU/L)

Natural

Stimulated

8.91依1.04

6.73依0.59

EF

0.012依0.009

0.004依0.004

8.97依0.79

LF

0.009依0.006

0.004依0.003

8.59依0.64

MF
ML

0.007依0.004

0.004依0.002

0.009依0.002

0.015依0.001

8.40依0.81

6.24依0.54

6.57依0.35
6.19依0.53

The stages of the cycles were early follicular (EF), mid-follicular (MF),

late follicular (LF), and mid-luteal (ML); aDetectable concentrations

were only seen in 6/10 women; bDetectable concentrations were seen in

10/11 women.

4. Discussion
4.1. Assays
The use of immunoassays allows precise quantitative
measurements to be made when measuring analytes.
However, different assays often have different characteristics
due to the choice of reagents or their calibration, resulting
in different numerical values. This is important when
comparing work from various laboratories or over a range of
time frames. For example, the expression of PAPP-A results in
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mIU/mL in the present study compared to 毺g/L elsewhere[43]
reflects the change in methodology and the move to a
different standardisation. Between-assay differences have
been reported when measuring CA15-3 with commercial
kits from different companies, resulting from differences in
calibration rather than specificity[44]. This is perhaps not too
surprising as many of the companies used similar capture
and signal antibodies in their sandwich immunometric assays.
CA125 can also show between-supplier variability, and large
differences have been reported between assays supplied by
Siemens and Panomics [45].
4.2. Changes during ovarian cycle
There were cycle dependent changes seen in CA125
concentrations for both natural and stimulated ovarian cycles.
This study showed that ovarian stimulation had no effect on
CA125 levels and that both natural and stimulated ovarian
cycles showed similar changing patterns. The results from the
natural group agreed with the literature in that the highest
CA125 levels were found during menstruation [46-50]. The
stimulated group results also agreed with the literature
where the highest CA125 levels were found in the luteal
phase of the cycle[51]. It is thought that the endometrium is
responsible for the cyclical changes in CA125 concentrations
and it is the disruption of the endometrium during menses
that allows increased amounts of CA 125 to enter the
blood stream[46, 52, 53]. It was also proposed that pregnancy
outcomes following ART treatment could be predicted by
measuring CA125 on the day of oocyte retrieval and that
levels >10IU/mL were correlated with an 86.6% positive
pregnancy rate based on a prospective study of 75 ART
cycles[54]. Of the 8 participants in this study that had a
CA125 of >10 U/mL before oocyte retrieval, only 3 of those
became pregnant ( 37 . 5 %) which was markedly lower
than the literature had suggested. T here was also one
participant who had a CA 125 level < 10 U /m L that did
become pregnant. Although our results seem to suggest
that CA125 levels >10 IU/mL are not as strongly correlated
to positive pregnancy rate as the previous study, they are
limited by the relatively small sample size. Nonetheless the
results of this study do warrant further investigation.
Serum concentrations of CA15-3 in natural menstrual
cycles were not statistically different to those found in
stimulated cycles. This suggests that ovarian stimulation per
se for the purposes of IVF and ICSI procedures does not affect
circulating serum CA15-3 levels. The CA15-3 concentration
did however show some interaction with the phases of the

94

Melissa Stemp et al./ Asian Pacific Journal of Reproduction (2014)90-96

cycles which is in agreement with the literature[55]. The MUC1
gene, which encodes the CA15-3 glycoprotein, is expressed in
the upper female reproductive tract and its function has been
suggested to be to prevent ectopic embryo implantation[25].
Other studies have shown that MUC1 expression is progesterone
dependent whereby it is up regulated in the luteal phase of the
menstrual cycle [26, 27]. These findings are significant because
if MUC1 is up-regulated by progesterone in the luteal phase,
it would suggest that it is a part of the body’s mechanisms to
avoid ectopic pregnancy. This current study has shown that
serum concentrations of CA15-3 are at their highest in the
mid-follicular phase of the natural menstrual cycle, which is
at a time that progesterone is at its lowest levels, suggesting
that although CA15-3 is encoded by the MUC1 gene, it does
not appear to be progesterone dependent. This being said,
the previous research on MUC1 expression was carried
out on tissue samples whereas this is an analysis of serum
concentrations so the ‘lag’ in peak CA15-3 concentrations
may not reflect activity at a local level.
Ohuchi et al[36] described CA72-4 as a useful tumour
marker for all tumours derived from epithelial cells
highlighting the tumour markers increased sensitivity to
gastric carcinoma compared to other tumour markers such
as CA19-9, CEA and CA125. It was also proposed that when
CA72-4 is used as a complimentary biomarker to CA125, the
sensitivity for detecting early stage ovarian cancer increased
from 45% to 70%[38]. The CA72-4 assay used in this research
failed to register any results above the assays lower limit of
detection in 40.0%-45.5% of individuals from both natural
and stimulated ovarian cycles. Of those individuals that
did have detectable levels of CA72-4, the results showed
an extremely high degree of variability both within each
individual (whereby each sample from the same cycle was
vastly different to the others) and between patients where the
difference was so large that there were no obvious patterns
of change. It was for these reasons that statistical analysis
was not carried out and it was concluded that the assay was
too unreliable for use as a diagnostic measure in the clinical
setting.
Total prostate-specific antigen (tPSA) was detectable in
60% of women in natural cycles and 91% of women during
stimulated ovarian cycles. T he range of mean results
from each phase was between 0.004 毺g/L-0.012 毺g/L for
both natural and stimulated ovarian cycles. There was no
significant relationship between tPSA concentration and
phase of the cycle, nor was there any significant difference
between tPSA concentrations in natural and stimulated

cycles. Zarghami et al. [56] has indicated that tPSA in the
menstrual cycle followed the progesterone concentration
peak with a 10-12 day delay. This finding is suggestive
of tPSA concentrations changing in a cyclical manner. In
our present study, we found that tPSA concentrations were
highest in the early follicular and late luteal phase, which
is relative to menstruation, although this did not reach
statistical significance. Total prostate specific antigen
concentrations are very low in female serum and it is not
known why some women have measurable levels of tPSA and
others do not. The physiological function of tPSA in females
is yet to be determined.
Finally, we found a significant difference in the mean
concentration of PAPP-A between natural and stimulated
ovarian cycles, where stimulated ovarian cycles were on
average (2.41±0.58) mIU/L lower than natural cycles. The
present study also showed that throughout each of the two
types of cycles there were no significant changes in PAPP-A
levels. Findings of lower serum PAPP-A concentrations in
women during stimulated ovarian cycles confirms previous
work where women were shown to have lower serum PAPP-A
levels with higher oocyte number after oocyte retrieval, leading
to the proposal that differences in PAPP-A concentrations may
be due to the presence of multiple follicles in the ovaries[16].
Amor et al. [13] found that PAPP-A levels were reduced
in both fresh and frozen-thawed embryo transfers when
compared to naturally conceived pregnancies. However,
fresh transfers did have significantly lower PAPP-A levels
than frozen-thawed transfers, providing evidence for the
multiple follicle theory where the ovaries in frozen-thawed
embryo transfer cycles are not hyperstimulated to create
multiple follicle development like those of fresh cycles.
In summary, batch analysis of all samples from each of the
participants was conducted to maximise the possibility that
any changes seen in biomarker concentrations were due to
biological fluctuations and not because of assay variability.
Ovarian stimulation reduced serum PAPP‐A levels, whilst
CA125 and CA15‐3 were generally unaffected by ovarian
stimulation but did have cyclical changes throughout both
natural and stimulated cycles.
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